AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

AstraZeneca (AZN) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia. The latest agreement is likely to strengthen AstraZeneca's cardiovascular pipeline, which is being studied for treating various cardiovascular diseases. Image Source: Zacks Investment Research Year to date, shares of AstraZeneca have rallied 14.1% compared with the ...